Decreased hippocampal metabolism in high-amyloid mild cognitive impairment

Alzheimer's and Dementia

Volumn 12, Issue 12, 2016, Pages 1288-1296

  Hanseeuw, Bernard J ^a   Schultz, Aaron P ^a   Betensky, Rebecca A ^b   Sperling, Reisa A ^a   Johnson, Keith A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alzheimer's disease; Amyloid; Association cortex; FDG PET; Hippocampus; Metabolism; Mild cognitive impairment

Indexed keywords

AMYLOID; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ARTICLE; ASSOCIATION CORTEX; BRAIN METABOLISM; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); EDUCATION; FEMALE; HIPPOCAMPUS; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; ATROPHY; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; IMAGE PROCESSING; METABOLISM; PATHOLOGY;

AGED; AMYLOID; ANILINE COMPOUNDS; ATROPHY; COGNITIVE DYSFUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84994461924     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.06.2357     Document Type: Article

References (42)

1. [1] Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82 (1991), 239–259.
2. [2] Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8 (2012), 1–13.
3. [3] Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004), 306–319.
4. [4] Petersen, R.C., Aisen, P., Boeve, B.F., Geda, Y.E., Ivnik, R.J., Knopman, D.S., et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74 (2013), 199–208.
5. [5] Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
6. [6] Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71 (2014), 1379–1385.
7. [7] Toledo, J.B., Weiner, M.W., Wolk, D.A., Da, X., Chen, K., Arnold, S.E., et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun, 2, 2014, 26.
8. [8] Bertens, D., Knol, D.L., Scheltens, P., Visser, P.J., Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimers Dement 11 (2015), 511–522.
9. [9] Jack, C.R. Jr, Lowe, V.J., Weigand, S.D., Wiste, H.J., Senjem, M.L., Knopman, D.S., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132 (2009), 1355–1365.
10. [10] Petersen, R.C., Mild cognitive impairment as a diagnostic entity. J Intern Med 256 (2004), 183–194.
11. [11] Roy, K., Pepin, L.C., Philiossaint, M., Lorius, N., Becker, J.A., Locascio, J.J., et al. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum. J Alzheimers Dis 42 (2014), 291–300.
12. [12] Herholz, K., Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert Rev Neurother 10 (2010), 1667–1673.
13. [13] Rousset, E., Harel, J., Dubreuil, J.D., Binding characteristics of Escherichia coli enterotoxin b (STb) to the pig jejunum and partial characterization of the molecule involved. Microb Pathog 24 (1998), 277–288.
14. [14] Johnson, K.A., Gregas, M., Becker, J.A., Kinnecom, C., Salat, D.H., Moran, E.K., et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62 (2007), 229–234.
15. [15] Logan, J., Fowler, J.S., Volkow, N.D., Wolf, A.P., Dewey, S.L., Schlyer, D.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10 (1990), 740–747.
16. [16] Nestor, P.J. Fryer, T.D., Smielewski, P., Hodges, J.R., Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 54 (2003), 343–351.
17. [17] Mevel, K., Desgranges, B., Baron, J.C., Landeau, B., De la Sayette, V., Viader, F., et al. Detecting hippocampal hypometabolism in Mild Cognitive Impairment using automatic voxel-based approaches. Neuroimage 37 (2007), 18–25.
18. [18] Mosconi, L., Tsui, W.H., De-Santi, S., Li, J., Rusinek, H., Convit, A., et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64 (2005), 1860–1867.
19. [19] De Santi, S., de Leon, M.J., Rusinek, H., Convit, A., Tarshish, C.Y., Roche, A., et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22 (2001), 529–539.
20. [20] Ishii, K., Sasaki, M., Yamaji, S., Sakamoto, S., Kitagaki, H., Mori, E., Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Dement Geriatr Cogn Disord 9 (1998), 317–322.
21. [21] Ishii, K., Sasaki, H., Kono, A.K., Miyamoto, N., Fukuda, T., Mori, E., Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 32 (2005), 959–963.
22. [22] Chetelat, G., Desgranges, B., Landeau, B., Mezenge, F., Poline, J.B., de-la-Sayette, V., et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 131 (2008), 60–71.
23. [23] Kawachi, T., Ishii, K., Sakamoto, S., Sasaki, M., Mori, T., Yamashita, F., et al. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 33 (2006), 801–809.
24. [24] Wu, L., Rowley, J., Mohades, S., Leuzy, A., Dauar, M.T., Shin, M., et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One, 7, 2012, e47905.
25. [25] Li, Y., Rinne, J.O., Mosconi, L., Pirraglia, E., Rusinek, H., DeSanti, S., et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35 (2008), 2169–2181.
26. [26] Bruck, A., Virta, J.R., Koivunen, J., Koikkalainen, J., Scheinin, N.M., Helenius, H., et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging 40 (2013), 1567–1572.
27. [27] Cohen, A.D., Klunk, W.E., Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis 72 Pt A (2014), 117–122.
28. [28] Cohen, A.D., Price, J.C., Weissfeld, L.A., James, J., Rosario, B.L., Bi, W., et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 29 (2009), 14770–14778.
29. [29] Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W.M., Ossenkoppele, R., et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology 84 (2015), 508–515.
30. [30] Ashraf, A., Fan, Z., Brooks, D.J., Edison, P., Cortical hypermetabolism in MCI subjects: a compensatory mechanism?. Eur J Nucl Med Mol Imaging 42 (2015), 447–458.
31. [31] Toledo, J.B., Cairns, N.J., Da, X., Chen, K., Carter, D., Fleisher, A., et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun, 1, 2013, 65.
32. [32] Pagani, M., Dessi, B., Morbelli, S., Brugnolo, A., Salmaso, D., Piccini, A., et al. MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings. Curr Alzheimer Res 7 (2010), 287–294.
33. [33] Grimmer, T., Wutz, C., Drzezga, A., Forster, S., Forstl, H., Ortner, M., et al. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res 10 (2013), 82–85.
34. [34] Ma, Y., Zhang, S., Li, J., Zheng, D.M., Guo, Y., Feng, J., et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a systematic review. Medicine (Baltimore), 93, 2014, e150.
35. [35] Wolk, D.A., Price, J.C., Saxton, J.A., Snitz, B.E., James, J.A., Lopez, O.L., et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65 (2009), 557–568.
36. [36] Huijbers, W., Mormino, E.C., Schultz, A.P., Wigman, S., Ward, A.M., Larvie, M., et al. Amyloid-beta deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain 138 (2015), 1023–1035.
37. [37] Landau, S.M., Harvey, D., Madison, C.M., Reiman, E.M., Foster, N.L., Aisen, P.S., et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75 (2010), 230–238.
38. [38] Barnes, J., Bartlett, J.W., van-de-Pol, L.A., Loy, C.T., Scahill, R.I., Frost, C., et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 30 (2009), 1711–1723.
39. [39] Tosun, D., Joshi, S., Weiner, M.W., Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann Neurol 74 (2013), 188–198.
40. [40] Marshall, G.A., Lorius, N., Locascio, J.J., Hyman, B.T., Rentz, D.M., Johnson, K.A., et al. Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum. J Alzheimers Dis 41 (2014), 719–728.
41. [41] Ye, B.S., Seo, SW., Kim, C.H., Jeon, S., Kim, G.H., Noh, Y., et al. Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment. Neurobiol Aging 35 (2014), 291–300.
42. [42] Jack, C.R. Jr., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71 (2012), 765–775.